The Lancet Oncology· 2015Q1
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
- 867citations
- Q1SCImago
- 2015year
Short summary
Adding bevacizumab to standard chemotherapy did not improve overall survival in women with newly diagnosed ovarian cancer, but did show a benefit in a subgroup of patients with poor-prognosis disease.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Reproductive Medicine
Reproductive MedicineMedicine